STFGX | VSTSX | STFGX / VSTSX | |
Total Expense Ratio | 0.12 | 0.01 | 1,200% |
Annual Report Gross Expense Ratio | 0.15 | 0.01 | 1,500% |
Fund Existence | 57 years | 9 years | - |
Gain YTD | 8.343 | 8.300 | 101% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 5000000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 8.41B | 1.91T | 0% |
Annual Yield % from dividends | 1.47 | 1.23 | 120% |
Returns for 1 year | 7.70 | 17.78 | 43% |
Returns for 3 years | 40.61 | 60.72 | 67% |
Returns for 5 years | 56.89 | 93.67 | 61% |
Returns for 10 years | 94.74 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ASVDX | 10.25 | 0.07 | +0.69% |
American Century Small Cap Value R6 | |||
VTSAX | 152.65 | 0.67 | +0.44% |
Vanguard Total Stock Mkt Idx Adm | |||
GCLLX | 17.21 | 0.06 | +0.35% |
Goldman Sachs Enhanced U.S. Equity C | |||
PDIAX | 22.54 | 0.07 | +0.31% |
Virtus KAR Equity Income A | |||
FBTAX | 28.16 | 0.01 | +0.04% |
Fidelity Advisor Biotechnology A |